Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
Thirteen patients were treated with a hydroxyurea -- 5-azacytidine combination in an attempt to show an increase in therapeutic efficacy of 5-azacytidine without increased bone marrow toxicity. Leukemic and nonleukemic patients were selected in order to compare the effect of a combination therapy on bone marrow. There was no clear-cut tumor response observed in evaluable patients. Overall activity of the combination, as judged by the onset of myelosuppression, appears to be higher than that of 5-azacytidine given alone.
D000328:Adult; D000368:Aged; D001374:Azacitidine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage* / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D001374:Azacitidine; D006918:Hydroxyurea